Alexandra Okmian | Senior Business Development and IR Manager |
Dror Ben-Asher | CEO |
Guy Goldberg | Chief Business Officer |
Gilead Raday | COO |
Rob Jackson | SVP, Sales and Marketing |
Micha Ben-Chorin | CFO |
Bob Gilkin | SVP, Market Access and Trade Relations |
Brandon Folkes | Cantor Fitzgerald |
Boobalan Pachaiyappan | H.C. Wainwright |
David Hoang | SMBC |
Robert Hazlett | BTIG |
Scott Henry | ROTH Capital |
Good day and thank you for standing by. Welcome to the RedHill Biopharma's Third Quarter 2021 Results Financial Conference Call. [Operator Instructions] At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Micha Ben-Chorin, Chief Financial Officer; Gilead Raday, Chief Operating Officer; Guy Goldberg, Chief Business Officer; Adi Frish, Chief Corporate and Business Development Officer; Rob Jackson, Senior Vice President, Sales and Marketing; Bob Gilkin, Senior VP, Market Access and Trade Relations; and Dr. June Almenoff, Chief Medical Officer.
Before we begin, we will read from the RedHill's Safe Harbor statement.